Logo

Pfizer’s Cibinqo (abrocitinib) Receives Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Share this
Pfizer’s Cibinqo (abrocitinib) Receives Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Pfizer’s Cibinqo (abrocitinib) Receives Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Shots:

  • Health Canada has approved Cibinqo for mod. to sev. AD in patients aged ≥12yrs. incl. the relief of pruritus who have had an inadequate response to other systemic drugs or for whom these treatments are not advisable. Cibinqo can be used with/out medicated topical therapies for AD
  • The physical symptoms include broken skin, dry skin all over, constant itching, redness, extensive skin thickening, oozing & cracking in those with AD frequently has psycho-social problems such as anxiety, insomnia & despair. Without appropriate care, the symptoms may worsen & have a detrimental influence on a patient's sleep habits & overall QoL
  • Cibinqo has received marketing authorization in the EU, Great Britain, Japan, Korea, the United Arab Emirates, Norway, Iceland, & Singapore

Ref: Newswire | Image: Pfizer

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions